BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...

Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. (“PharmaEssentia”) and AOP Orphan ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Reports Q4 revenue $170.6M vs. $60M last year. “Protagonist is quickly approaching multiple late-stage transformational events expected in the ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research note issued to investors on Friday,RTT News reports.

(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate ...